Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q1 2024 · 10-Q
Revenue$0.00$0.00no prior Q1 2023 on file Net Income-$47.93M-$47.93MN/M vs Q1 2023 EPS Diluted-$0.62-$0.62N/M vs Q1 2023 Operating Income-$59,041,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
Free Cash Flowderived-$46,375,000N/M ended Mar 31, 2024 · filed May 9, 2024 · 39 d after period end